Implantica (IMP) Q3 2025 earnings summary

Executive summary

• Significant progress toward U.S. FDA approval for RefluxStopⓇ, with successful inspections, regulatory milestones, and strong clinical and economic evidence supporting its superiority over existing treatments.

• U.S. market launch preparations are advanced, including production ramp-up, validated manufacturing in the U.S. and Europe, and engagement with key opinion leaders.

• NICE in the U.K. has approved or recommended RefluxStopⓇ for NHS public hospitals and severe IEM/GERD cases, expanding market potential and reimbursement opportunities.

• Main competitor has withdrawn from non-U.S. markets, improving RefluxStopⓇ's competitive position and expanding its addressable market.

• Strong clinical data published, including 5-year outcomes, real-world studies, and 27 manuscripts accepted or published.

Financial highlights

• Q3 net sales increased 6% year-over-year to EUR 365,000; nine-month net sales up 3% to EUR 1,543,000.

• Adjusted gross margin was 93% in Q3 (down from 97%); nine-month margin improved to 94% (from 93%).

• Q3 operating loss (EBIT) decreased 17% year-over-year to EUR 4.4 million; nine-month EBIT loss reduced by 28%.

• Operating cash outflow for Q3 was EUR 3.3 million, down 32% year-over-year; nine-month operating cashflow down 34%.

• Cash and short-term investments totaled EUR 53.3 million at quarter-end.

Outlook and guidance

• FDA approval for RefluxStopⓇ is expected in the second half of Q1, with a clear path to U.S. market entry and operational readiness for rapid scale-up.

• U.S. hospital contracts expected to take at least three months post-approval before surgeries can begin.

• Expansion in the U.K. anticipated following NICE recommendation; regulatory submissions for Japan, Canada, and Brazil planned for 2026.

• R&D and new product launches are on hold until after U.S. launch.